This protocol addresses portal hypertension in a patient with underlying liver cirrhosis who has developed hepatic hydrothorax alongside ascites — a clinically complex presentation requiring targeted management.
The patient has liver cirrhosis with ascites and has developed hepatic hydrothorax — an accumulation of pleural fluid driven by portal hypertension. Hydrothorax is common in patients with ascites, arising as a direct complication of the underlying cirrhotic process.
Management involves a combination of diuretic-based strategies and vasoconstrictor therapy aimed at controlling the hepatic hydrothorax. The full protocol specifies the selection, sequencing, and clinical targets in detail.
Hydrothorax is common in patients with ascites.
Apart from diuretics and salt restriction, vasoconstrictors such as oral midodrine and intravenous terlipressin can be used to control hepatic hydrothorax.
DOI: 10.1016/j.jceh.2022.03.002
View source ↗